Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — 505(b)(2) literature-to-product bridge table — after a site-change that invalidates stability claims. RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT has 505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims. If that extract cannot support to drop a secondary, the only defensible Pharma & Life Sciences Pharmacovigilance output is hold.

DECISION RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. The population in 505(b)(2) literature-to-product bridge table is the one a site-change that invalidates stability claims named, so Proceed under protocol follows for this Pharmacovigilance file. 2. The population in 505(b)(2) literature-to-product bridge table is adjacent only to a site-change that invalidates stability claims; Pause the pathway is the honest Pharma & Life Sciences call. 3. An RWE group proposing a post-marketing study instead of a new RCT already contained a site-change that invalidates stability claims before 505(b)(2) literature-to-product bridge table arrived; no new Pharmacovigilance path. 4. Provenance on 505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim RWE evidence-strategy director would keep. 2. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 3. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims. 4. For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against a site-change that invalidates stability claims and write the one fact that would move to drop a secondary for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT.